Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Harvard Bioscience (HBIO) stocks in Canada

Learn how to easily invest in Harvard Bioscience stocks.

Harvard Bioscience is a medical instruments & supplies business based in the US. Harvard Bioscience stocks (HBIO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $8.03 – an increase of 10.2% over the previous week. Harvard Bioscience employs 475 staff and has a trailing 12-month revenue of around $118.9 million.

How to buy stocks in Harvard Bioscience

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – HBIO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Harvard Bioscience stock price (NASDAQ:HBIO)

Use our graph to track the performance of HBIO stocks over time.

Harvard Bioscience shares at a glance

Information last updated 2022-05-11.
Latest market close$3.78
52-week range$3.36 - $8.75
50-day moving average $5.70
200-day moving average $6.73
Wall St. target price$10.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.01

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
OFFER
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get $500 in commission free trades when you fund your account with a minimum of $10,000. Conditions apply. Ends August 31st, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Harvard Bioscience stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Harvard Bioscience price performance over time

Historical closes compared with the close of $3.78 from 2022-05-13

1 week (2022-05-05) N/A
1 month (2022-04-14) -35.71%
3 months (2022-02-12) N/A
6 months (2021-11-16) -51.91%
1 year (2021-05-14) -46.08%
2 years (2020-05-15) 46.51%
3 years (2019-05-16) 59.49%
5 years (2017-05-16) 57.50%

Is Harvard Bioscience under- or over-valued?

Valuing Harvard Bioscience stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Harvard Bioscience's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Harvard Bioscience's PEG ratio

Harvard Bioscience's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.89. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Harvard Bioscience's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Harvard Bioscience's EBITDA

Harvard Bioscience's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $9.7 million.

The EBITDA is a measure of a Harvard Bioscience's overall financial performance and is widely used to measure a its profitability.

Harvard Bioscience financials

Revenue TTM $118.9 million
Operating margin TTM 1.74%
Gross profit TTM $67.7 million
Return on assets TTM 0.81%
Return on equity TTM -0.36%
Profit margin -0.24%
Book value $2.03
Market capitalisation $158 million

TTM: trailing 12 months

Harvard Bioscience share dividends

We're not expecting Harvard Bioscience to pay a dividend over the next 12 months.

Have Harvard Bioscience's shares ever split?

Harvard Bioscience's shares were split on a 1319:1000 basis on 3 November 2013. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1319 shares. This wouldn't directly have changed the overall worth of your Harvard Bioscience shares – just the quantity. However, indirectly, the new 24.2% lower share price could have impacted the market appetite for Harvard Bioscience shares which in turn could have impacted Harvard Bioscience's share price.

Harvard Bioscience share price volatility

Over the last 12 months, Harvard Bioscience's shares have ranged in value from as little as $3.36 up to $8.75. A popular way to gauge a stock's volatility is its "beta".

HBIO.US volatility(beta: 1.85)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Harvard Bioscience's is 1.851. This would suggest that Harvard Bioscience's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Harvard Bioscience overview

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site